Hospital Universitario Ramón y Cajal

Madrid, Madrid 28034

1 studies enrolling now · 6 studies all time

What they study most

HER2-positive Breast Cancer, HER2-positive Colorectal Cancer, HER2-positive Endometrial Cancer, HER2-positive Gastroesophageal Cancer, HER2-positive Solid Tumors, IgG4 Related Disease, Metastatic Breast Cancer, Relapsed Small Cell Lung Cancer, Renal Cell Carcinoma, Venous Thromboembolism

Studies at this site

• Computerized Registry of Patients With Venous Thromboembolism (RIETE) — Recruiting now
• Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) — Completed
• Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype — Stopped early
• Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma — Completed
• A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease — Running, not enrolling
• A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors — Stopped early